John F Dipersio

List of Publications by Citations

354 papers	10,929 citations	45 h-index	101 g-index
394 ext. papers	13,856 ext. citations	5.3 avg, IF	5.92 L-index

#	Paper	IF	Citations
354	Age-related mutations associated with clonal hematopoietic expansion and malignancies. *Nature Medicine*, **2014**, 20, 1472-8	50.5	1125
353	ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 625-638	4.7	874
352	Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. *Blood*, **2009**, 113, 5720-6	2.2	597
351	Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. *Journal of Clinical Oncology*, **2009**, 27, 4767-73	2.2	533
350	Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. *Nature*, **2015**, 518, 552-555	50.4	503
349	TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. *New England Journal of Medicine*, **2016**, 375, 2023-2036	59.2	493
348	Pathogenic Germline Variants in 10,389 Adult Cancers. *Cell*, **2018**, 173, 355-370.e14	56.2	342
347	SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. *PLoS Computational Biology*, **2014**, 10, e1003665	5	301
346	Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. *Cancer Cell*, **2014**, 25, 379-92	24.3	273
345	Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. *Biology of Blood and Marrow Transplantation*, **2008**, 14, 1045-1056	4.7	267
344	Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. *JAMA - Journal of the American Medical Association*, **2015**, 314, 811-22	27.4	242
343	Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. *Journal of Hematology and Oncology*, **2017**, 10, 55	22.4	208
342	Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. *Blood*, **2001**, 98, 266-71	2.2	203
341	First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. *Blood*, **2018**, 131, 2515-2527	2.2	194
340	Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. *Haematologica*, **2015**, 100, 479-88	6.6	174
339	An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. *Leukemia*, **2018**, 32, 1970-1983	10.7	173
338	Patterns and functional implications of rare germline variants across 12 cancer types. *Nature Communications*, **2015**, 6, 10086	17.4	170

337	Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. *New England Journal of Medicine*, **2018**, 379, 2330-2341	59.2	165
336	Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. *Blood*, **2015**, 126, 2484-90	2.2	150
335	CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression. *Cell*, **2017**, 168, 801-816.e13	56.2	131
334	Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 1761-9	4.7	103
333	Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. *Nature Communications*, **2018**, 9, 455	17.4	99
332	Advances in stem cell mobilization. *Blood Reviews*, **2014**, 28, 31-40	11.1	98
331	IFNR signaling mediates alloreactive T-cell trafficking and GVHD. *Blood*, **2012**, 120, 4093-103	2.2	97
330	Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing. *PLoS Genetics*, **2014**, 10, e1004462	6	94
329	Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1851-1860	4.7	91
328	Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. *PLoS ONE*, **2014**, 9, e109799	3.7	89
327	Thrombopoietin therapy increases platelet yields in healthy platelet donors. *Blood*, **2001**, 98, 1339-45	2.2	81
326	Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. *Blood*, **2016**, 127, 893-7	2.2	80
325	Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. *Blood*, **2021**, 137, 751-762	2.2	77
324	Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 46-52	4.7	72
323	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 2305-2321	4.7	68
322	Diabetic stem-cell "mobilopathy". *New England Journal of Medicine*, **2011**, 365, 2536-8	59.2	67
321	Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 651-657	4.7	64
320	Mutation Clearance after Transplantation for Myelodysplastic Syndrome. *New England Journal of Medicine*, **2018**, 379, 1028-1041	59.2	64

319	Gold Nanoclusters Doped with (64)Cu for CXCR4 Positron Emission Tomography Imaging of Breast Cancer and Metastasis. *ACS Nano*, **2016**, 10, 5959-70	16.7	56
318	CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. *Blood*, **2020**, 136, 2308-2318	2.2	55
317	Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease. *Bone Marrow Transplantation*, **2018**, 53, 826-831	4.4	55
316	Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation. *Transplant Infectious Disease*, **2017**, 19, e12629	2.7	55
315	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. *Biology of Blood and Marrow Transplantation*, **2019**, 25, e76-e85	4.7	53
314	Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia. *Cancer*, **2017**, 123, 3061-3072	6.4	52
313	Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. *Science Translational Medicine*, **2020**, 12,	17.5	50
312	Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia. *Molecular Cancer Therapeutics*, **2018**, 17, 1739-1751	6.1	49
311	Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. *Blood*, **2017**, 129, 2680-2692	2.2	48
310	The Role of Biomarkers in the Diagnosis and Risk Stratification of Acute Graft-versus-Host Disease: A Systematic Review. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1552-1564	4.7	48
309	Radionuclides transform chemotherapeutics into phototherapeutics for precise treatment of disseminated cancer. *Nature Communications*, **2018**, 9, 275	17.4	44
308	Divergent viral presentation among human tumors and adjacent normal tissues. *Scientific Reports*, **2016**, 6, 28294	4.9	44
307	Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia: A Retrospective Single-Center Review. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1696-1701	4.7	44
306	Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor. *Diabetes*, **2015**, 64, 2969-77	0.9	43
305	The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1125-1134	4.7	43
304	Targeting the leukemia-stroma interaction in acute myeloid leukemia: rationale and latest evidence. *Therapeutic Advances in Hematology*, **2016**, 7, 40-51	5.7	42
303	Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers. *New England Journal of Medicine*, **2021**, 384, 924-935	59.2	42
302	Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. *Leukemia*, **2018**, 32, 2483-2494	10.7	41

301	TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. *Blood Advances*, **2020**, 4, 5011-5024	7.8	41
300	A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1581-1589	4.7	38
299	Preclinical Development of CD38-Targeted [Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma. *Journal of Nuclear Medicine*, **2018**, 59, 216-222	8.9	37
298	Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials. *Blood*, **2016**, 128, 763-73	2.2	37
297	Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial. *Blood*, **2014**, 124, 3135-3135	21.3	35
296	Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia. *Experimental Hematology*, **2016**, 44, 603-13	3.1	33
295	Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4. *Cancer Cell*, **2014**, 25, 530-42	24.3	33
294	Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia. *Clinical Cancer Research*, **2017**, 23, 3385-3395	12.9	31
293	Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia. *Cancer Discovery*, **2020**, 10, 1854-1871	24.4	30
292	T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 648-653	4.7	28
291	Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, 443-9	2	28
290	Transfer of Cell-Surface Antigens by Scavenger Receptor CD36 Promotes Thymic Regulatory T Cell Receptor Repertoire Development and Allo-tolerance. *Immunity*, **2018**, 48, 923-936.e4	32.3	28
289	Relevance and clinical implications of tumor cell mobilization in the autologous transplant setting. *Biology of Blood and Marrow Transplantation*, **2011**, 17, 943-55	4.7	28
288	Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 1736-1743	4.7	26
287	Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents. *Journal of Nuclear Medicine*, **2016**, 57, 640-5	8.9	26
286	Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation. *Leukemia Research*, **2016**, 49, 1-6	2.7	26
285	A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. *Blood Cancer Journal*, **2018**, 8, 35	7	25
284	Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation. *Science Translational Medicine*, **2020**, 12,	17.5	24

283	Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1187-1195	4.7	24
282	Azacitidine Mitigates Graft-versus-Host Disease via Differential Effects on the Proliferation of T Effectors and Natural Regulatory T Cells In Vivo. *Journal of Immunology*, **2017**, 198, 3746-3754	5.3	23
281	A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial. *Blood*, **2012**, 120, 163-163	2.2	23
280	Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1324-1329	4.7	22
279	Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma. *Nature Communications*, **2020**, 11, 6037	17.4	21
278	Fresh or Cryopreserved CD34-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 1072-1077	4.7	20
277	Dynamic host immune response in virus-associated cancers. *Communications Biology*, **2019**, 2, 109	6.7	20
276	Bortezomib is a rapid mobilizer of hematopoietic stem cells in mice via modulation of the VCAM-1/VLA-4 axis. *Blood*, **2014**, 124, 2752-4	2.2	20
275	Targeting VLA4 integrin and CXCR2 mobilizes serially repopulating hematopoietic stem cells. *Journal of Clinical Investigation*, **2019**, 129, 2745-2759	15.9	20
274	Enhanced in utero allogeneic engraftment in mice after mobilizing fetal HSCs by 41/7 inhibition. *Blood*, **2016**, 128, 2457-2461	2.2	20
273	Steroids Versus Steroids Plus Additional Agent in Frontline Treatment of Acute Graft-versus-Host Disease: A Systematic Review and Meta-Analysis of Randomized Trials. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1133-1137	4.7	19
272	OMIP-042: 21-color flow cytometry to comprehensively immunophenotype major lymphocyte and myeloid subsets in human peripheral blood. *Cytometry Part A: the Journal of the International Society for Analytical Cytology*, **2018**, 93, 186-189	4.6	18
271	Caspase-9 is required for normal hematopoietic development and protection from alkylator-induced DNA damage in mice. *Blood*, **2014**, 124, 3887-95	2.2	18
270	Targeting CXCR4 in AML and ALL. *Frontiers in Oncology*, **2020**, 10, 1672	5.3	18
269	Mobilized peripheral blood: an updated perspective. *F1000Research*, **2019**, 8,	3.6	17
268	Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 2065-2069	4.7	16
267	[(18)F]FHBG PET/CT Imaging of CD34-TK75 Transduced Donor T Cells in Relapsed Allogeneic Stem Cell Transplant Patients: Safety and Feasibility. *Molecular Therapy*, **2015**, 23, 1110-1122	11.7	15
266	A Phase I Trial of Janus Kinase (JAK) Inhibition with INCB039110 in Acute Graft-Versus-Host Disease (aGVHD). *Blood*, **2016**, 128, 390-390	2.2	15

265	GPR18 Controls Reconstitution of Mouse Small Intestine Intraepithelial Lymphocytes following Bone Marrow Transplantation. *PLoS ONE*, **2015**, 10, e0133854	3.7	15
264	Risk for Infection After Allogeneic Hematopoietic Cell Transplant Remains Elevated in the Postengraftment Period. *Transplantation Direct*, **2017**, 3, e145	2.3	14
263	NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2015**, 13, 1337-46	7.3	14
262	Integrative omics analyses broaden treatment targets in human cancer. *Genome Medicine*, **2018**, 10, 60	14.4	13
261	A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma. *Clinical Cancer Research*, **2019**, 25, 7004-7013	12.9	13
260	Targeting CD123 In Leukemic Stem Cells Using Dual Affinity Re-Targeting Molecules (DARTs). *Blood*, **2013**, 122, 360-360	2.2	13
259	Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 1153-4	4.7	12
258	Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). *Blood*, **2018**, 132, 1455-1455	2.2	12
257	Non-Myeloablative Hematopoietic Stem Cell Transplantation in Older Patients with AML and MDS: Results from the Center for International Blood and Marrow Transplant Research (CIBMTR). *Blood*, **2008**, 112, 346-346	2.2	12
256	The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia. *Blood*, **2015**, 126, 2546-2546	2.2	12
255	GENESIS: Phase III trial evaluating BL-8040´+´G-CSF to mobilize hematopoietic cells for autologous transplant in myeloma. *Future Oncology*, **2019**, 15, 3555-3563	3.6	12
254	The use of ruxolitinib for acute graft-versus-host disease developing after solid organ transplantation. *American Journal of Transplantation*, **2020**, 20, 589-592	8.7	12
253	Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy. *Leukemia*, **2021**, 35, 2346-2357	11.7	12
252	Diabetes mellitus as a poor mobilizer condition. *Blood Reviews*, **2018**, 32, 184-191	11.1	12
251	Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantation. *Cancer*, **2017**, 123, 1800-1809	6.4	11
250	Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen. *Cancer Medicine*, **2017**, 6, 2814-2821	4.8	11
249	Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients. *Blood*, **2019**, 134, 733-733	2.2	11
248	Immune Responses in AML Patients Following Vaccination with GRNVAC1, Autologous RNA Transfected Dendritic Cells Expressing Telomerase Catalytic Subunit hTERT.. *Blood*, **2009**, 114, 633-633	2.2	11

247	Co-evolution of tumor and immune cells during progression of multiple myeloma. *Nature Communications*, **2021**, 12, 2559	17.4	11
246	Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib. *Blood Cancer Journal*, **2018**, 8, 88	7	11
245	Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 2047-2055	4.7	11
244	Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia. *Leukemia Research*, **2015**, 39, 1437-42	2.7	10
243	Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic. *Blood*, **2020**, 136, 43-44	2.2	10
242	Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation. *Blood*, **2011**, 118, 109-109	2.2	10
241	Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 1425-30	4.7	9
240	A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia. *Leukemia and Lymphoma*, **2016**, 57, 728-30	1.9	9
239	Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 2216-2223	4.7	9
238	Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 □CD3 Bispecific Dart□ Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia. *Blood*, **2018**, 132, 444-444	2.2	9
237	Phase II Study of Low-Dose Decitabine for the Front-Line Treatment of Older Patients with Acute Myeloid Leukemia (AML).. *Blood*, **2006**, 108, 1984-1984	2.2	9
236	A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.. *Blood*, **2009**, 114, 3693-3693	2.2	9
235	A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT). *Blood*, **2016**, 128, 505-505	2.2	9
234	A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome. *Leukemia and Lymphoma*, **2016**, 57, 2535-40	1.9	9
233	Peritransplant Serum Albumin Decline Predicts Subsequent Severe Acute Graft-versus-Host Disease after Mucotoxic Myeloablative Conditioning. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1137-1141	4.7	9
232	Shared cell of origin in a patient with Erdheim-Chester disease and acute myeloid leukemia. *Haematologica*, **2019**, 104, e373-e375	6.6	8
231	Suicide genes: monitoring cells in patients with a safety switch. *Frontiers in Pharmacology*, **2014**, 5, 241	5.6	8
230	Mobilization and Chemosensitization of AML with the CXCR4 Antagonist Plerixafor (AMD3100): A Phase I/II Study of AMD3100+MEC in Patients with Relapsed or Refractory Disease.. *Blood*, **2008**, 112, 1944-1944	2.2	8

229	Prolonged Administration of the Telomerase Vaccine GRNVAC1 Is Well Tolerated and Appears to Be Associated with Favorable Outcomes In High-Risk Acute Myeloid Leukemia (AML). *Blood*, **2010**, 116, 2190-2190	2.2	8
228	Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I. *Blood*, **2011**, 118, 278-278	2.2	8
227	Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I. *Blood*, **2012**, 120, 800-800	2.2	8
226	Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial. *Blood*, **2013**, 122, 1498-1498	2.2	8
225	Can every patient be mobilized?. *Best Practice and Research in Clinical Haematology*, **2010**, 23, 519-23	4.2	7
224	Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia. *Blood*, **2020**, 136, 16-18	2.2	7
223	Characterization of Human CD34+ Hematopoietic Stem Cells Following Administration of G-CSF or Plerixafor. *Blood*, **2008**, 112, 3476-3476	2.2	7
222	Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial. *Blood*, **2013**, 122, 650-650	2.2	7
221	Ruxolitinib As Sparing Agent for Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD). *Blood*, **2015**, 126, 1938-1938	2.2	7
220	Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?. *Frontiers in Oncology*, **2020**, 10, 608916	5.3	7
219	Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia. *Haematologica*, **2020**, 105, e404-e407	6.6	6
218	Insights into the role of the JAK/STAT signaling pathway in graft--host disease. *Therapeutic Advances in Hematology*, **2020**, 11, 2040620720914489	5.7	6
217	Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 2155-2158	4.7	6
216	Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 2199-2204	4.7	6
215	Chimeric Antigen Receptor T Cells Specific for CLL-1 for Treatment of Acute Myeloid Leukemia. *Blood*, **2018**, 132, 2205-2205	2.2	6
214	HLA-Matched Sibling Donor Stem Cell Mobilization Can Be Safely and Effectively Reduced from a Five Day to a One Day Process by a Direct Antagonist of the CXCR4/SDF-1 Interaction.. *Blood*, **2006**, 108, 53-53	2.2	6
213	A Phase II Multicenter Study of Lenalidomide in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL): Preliminary Results. *Blood*, **2008**, 112, 2595-2595	2.2	6
212	Preliminary Results of a Multicenter Phase II Trial of 5-Day Decitabine as Front-Line Therapy for Elderly Patients with Acute Myeloid Leukemia (AML). *Blood*, **2008**, 112, 560-560	2.2	6

211	Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML. *Blood*, **2017**, 130, 816-816	2.2	6
210	Remobilization of hematopoietic stem cells in healthy donors for allogeneic transplantation. *Transfusion*, **2016**, 56, 2331-5	2.9	6
209	Radioimmunotherapy-based conditioning for hematopoietic stem cell transplantation: Another step forward. *Blood Reviews*, **2016**, 30, 389-99	11.1	6
208	BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. *Cancer*, **2021**, 127, 1246-1259	6.4	6
207	Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation. *Journal of Clinical Oncology*, **2021**, 39, 386-396	2.2	6
206	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. *Nature Communications*, **2021**, 12, 5086	17.4	6
205	Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post-allogeneic hematopoietic stem cell transplant patient. *Blood Advances*, **2020**, 4, 2387-2391	7.8	5
204	Acute graft-versus-host disease following lung transplantation in a patient with a novel mutation. *Thorax*, **2018**, 73, 489-492	7.3	5
203	Acute lymphoblastic leukemia presenting with hypereosinophilia: Case report and review of the literature. *Blood Cells, Molecules, and Diseases*, **2017**, 65, 97-100	2.1	5
202	VLA4-Targeted Nanoparticles Hijack Cell Adhesion-Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival. *Clinical Cancer Research*, **2021**, 27, 1974-1986	12.9	5
201	Bortezomib (Velcade) When Given Pretransplant and Once Weekly as Consolidation Therapy Following High Dose Chemotherapy (HDCT) Leads to High Rates of Reactivation of Varicella Zoster Virus (VZV).. *Blood*, **2005**, 106, 3237-3237	2.2	5
200	Rapid Mobilization of Long Term Repopulating Hematopoietic Stem Cells (HSC) with AMD15057, a Small Molecule Inhibitor of VLA4; Synergism with AMD3100 and G-CSF. *Blood*, **2008**, 112, 615-615	2.2	5
199	Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 1282-1289	4.7	4
198	Selective targeting of 41 integrin attenuates murine graft versus host disease. *Leukemia*, **2020**, 34, 3100-3104	10.7	4
197	Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice. *Blood*, **2018**, 131, 2594-2596	2.2	4
196	Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS. *Blood*, **2019**, 134, 3915-3915	2.2	4
195	The Dual PI3K Inhibitor Duvelisib Potently Inhibits IL-6 Production and Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function in Vitro and In Vivo. *Blood*, **2020**, 136, 1-2	2.2	4
194	A Pilot Study Evaluating the Safety and Efficacy of AMD3100 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients with Advanced Hematological Malignancies.. *Blood*, **2004**, 104, 3341-3341	2.2	4

193	A Phase I Pharmacokinetic Trial of Decitabine Administered as a 3-Hour Infusion to Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS).. *Blood*, **2005**, 106, 1854-1854	2.2	4
192	AMD3100 Mobilizes Acute Promyelocytic Leukemia Cells from the Bone Marrow into the Peripheral Blood and Sensitizes Leukemia Cells to Chemotherapy.. *Blood*, **2005**, 106, 246-246	2.2	4
191	A Phase I/II Study of Chemosensitization with the CXCR4 Antagonist Plerixafor in Relapsed or Refractory AML.. *Blood*, **2009**, 114, 787-787	2.2	4
190	A Phase II Study of High Dose Lenalidomide as Initial Therapy for Acute Myeloid Leukemia in Patients > 60 Years Old.. *Blood*, **2009**, 114, 842-842	2.2	4
189	Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial. *Blood*, **2012**, 120, 3763-3763	2.2	4
188	Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs). *Blood*, **2013**, 122, 1496-1496	2.2	4
187	Infusion of Donor Lymphocytes Genetically Engineered to Express the Herpes Simplex Virus Thymidine Kinase (HSV-TK) Suicide Gene after Haploidentical Hematopoietic Stem Cell Transplantation (HSCT): Preliminary Efficacy Data from the Randomized TK008 Study. *Blood*, **2014**, 124, 2535-2535	2.2	4
186	PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation.. *Journal of Clinical Oncology*, **2012**, 30, 6503-6503	2.2	4
185	The Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) Score for HLA Class I Graft-versus-Host Disparity Is Associated with Increased Acute Graft-versus-Host Disease in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 123-131	4.7	4
184	Development of [Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 1302-1311	8.8	4
183	Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19.. *Journal of Virology*, **2022**, e0005722	6.6	4
182	Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington University and meta-analysis of published data. *Leukemia Research*, **2018**, 72, 86-91	2.7	3
181	New hope for mobilization failures . . . again. *Biology of Blood and Marrow Transplantation*, **2012**, 18, 159-60	4.7	3
180	Improvement in Cytokine Release Syndrome Management for the Treatment of AML Patients with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy. *Blood*, **2019**, 134, 5144-5144	2.2	3
179	Reduced Intensity Conditioning Therapy Using Campath -1H Is Successful for Stem Cell Transplantation in Non-Malignant Disorders.. *Blood*, **2004**, 104, 1823-1823	2.2	3
178	Human CD34+Cells Mobilized by AMD3100 Demonstrate Enhanced NOD/SCID Repopulating Function Compared to CD34+ Cells Mobilized by Granulocyte Colony Stimulating Factor.. *Blood*, **2005**, 106, 1962-1962	2.2	3
177	AMD3100 + G-CSF Improves Hematopoietic Progenitor Cell (HPC) Collection in Patients with Hodgkin's Disease (HD).. *Blood*, **2005**, 106, 1979-1979	2.2	3
176	A Mobilizing Regimen of AMD3100 and G-CSF Increases Stem Cell Collection in Patients with Hodgkin's Disease, and PK Is Similar to That of Non-Cancer Patients.. *Blood*, **2006**, 108, 3053-3053	2.2	3

175	Kinetics of Human and Murine Mobilization of Acute Myeloid Leukemia in Response to AMD3100.. *Blood*, **2007**, 110, 867-867	2.2	3
174	Months Report from the Phase 3 Study of Plerixafor+G-CSF VS. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with NHL.. *Blood*, **2008**, 112, 1136-1136	2.2	3
173	Mobilization with Plerixafor (Mozobil) Plus G-CSF Results in Superior Day 1 Collection of CD34+ Cells Compared to Placebo Plus G-CSF: Results From Two Randomized Placebo-Controlled Trials in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma.. *Blood*, **2009**, 114, 3224-3224	2.2	3
172	A Phase II Study Of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) As Conditioning Regimen Prior To Second Autologous Stem Cell Transplantation For Multiple Myeloma. *Blood*, **2013**, 122, 5492-5492	2.2	3
171	The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia. *Blood*, **2016**, 128, 2745-2745	2.2	3
170	Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation. *Journal of Clinical Investigation*, **2021**,	15.9	3
169	Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFR. *Leukemia*, **2021**,	10.7	3
168	Mobilization of Autologous Peripheral Blood Hematopoietic Cells for Cellular Therapy590-604		3
167	A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, e588-e593	2	2
166	Serendipity: decitabine monotherapy induced complete molecular response in a 77-year-old patient with acute promyelocytic leukemia. *Haematologica*, **2019**, 104, e170-e173	6.6	2
165	Selected biological issues affecting relapse after stem cell transplantation: role of T-cell impairment, NK cells and intrinsic tumor resistance. *Bone Marrow Transplantation*, **2018**, 53, 949-959	4.4	2
164	Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells. *Leukemia*, **2021**,	10.7	2
163	Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123 CD3 Bispecific Dart Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia. *Blood*, **2019**, 134, 460-460	2.2	2
162	Rapid and Robust Mobilization of CD34+ HSCs without G-CSF Following Administration of Mgta-145 Alone or in Combination with Plerixafor. *Blood*, **2019**, 134, 1961-1961	2.2	2
161	Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide. *Blood*, **2019**, 134, 4496-4496	2.2	2
160	Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab. *Blood*, **2020**, 136, 19-21	2.2	2
159	Allogeneic Hematopoietic Stem Cell Transplant Versus No Transplant in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission and Complete Molecular Remission. *Blood*, **2020**, 136, 46-48	2.2	2
158	Mgta-145, in Combination with Plerixafor in a Phase 1 Clinical Trial, Mobilizes Large Numbers of Human Hematopoietic Stem Cells and a Graft with Immunosuppressive Effects for Allogeneic Transplant. *Blood*, **2020**, 136, 31-32	2.2	2

157	Similar 5-Year Survival after Peripheral Blood Autotransplants (AutoPB) Versus HLA Matched Sibling Myeloablative Transplants (AlloBMT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1).. *Blood*, **2008**, 112, 2168-2168	2.2	2
156	12 Months Report from a Phase 3 Study of Plerixafor+G-CSF Vs. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with Multiple Myeloma. *Blood*, **2008**, 112, 3312-3312	2.2	2
155	Plerixafor (Mozobi) Plus G-CSF Is More Effective Than Placebo Plus G-CSF in Mobilizing CD34+ Hematopoietic Stem Cells in Patients with Multiple Myeloma Who Have Low (. *Blood*, **2009**, 114, 3230-3230	2.2	2
154	Plerixafor Plus G-CSF Is An Effective Regimen to Mobilize Hematopoietic Stem Cells in NHL Patients with Circulating Peripheral Blood CD34+ Cells/ Blood, **2009**, 114, 33-33	2.2	2
153	Comparison of Outcomes for Non-Myeloablative (NMA) and Myeloablative (MA) Conditioning for Adults with Acute Lymphoblastic Leukaemia (ALL) in First and Second Complete Remission (CR): a Center for International Blood and Marrow Transplant Research (CIBMTR) Analyisis.. *Blood*, **2009**, 114, 872-872	2.2	2
152	Phase I Study of Panobinostat Plus Decitabine In Elderly Patients with Advanced MDS or AML.. *Blood*, **2010**, 116, 1060-1060	2.2	2
151	Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF,. *Blood*, **2011**, 118, 3842-3842	2.2	2
150	Efficacy and Safety Of Ponatinib Following Failure Of Nilotinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial. *Blood*, **2013**, 122, 2738-2738	2.2	2
149	Impact of Immune Reconstitution (IR) and Graft-Versus-Host Disease (GvHD) on Clinical Outcomes after Treatment with Donor T Cells Transduced to Express the Herpes Simplex Virus Thymidine-Kinase Suicide Gene (TK cells) in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation (HSCT). *Blood*, **2016**, 128, 4599-4599	2.2	2
148	Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy.. *Journal of Clinical Oncology*, **2012**, 30, 6624-6624	2.2	2
147	Normal Myeloid Cells Are Required for Sustained CAR T Cell Activity Against Myeloid Tumor in a Humanized Mouse Model. *Blood*, **2021**, 138, 734-734	2.2	2
146	Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. *Blood*, **2021**,	2.2	2
145	3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance. *Leukemia and Lymphoma*, **2021**, 62, 2457-2465	1.9	2
144	The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal acute myeloid leukemia. *Leukemia and Lymphoma*, **2016**, 57, 1977-9	1.9	2
143	Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. *Leukemia Research*, **2021**, 110, 106713	2.7	2
142	Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia. *JCO Precision Oncology*, **2021**, 5,	3.6	2
141	Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia.. *Science Translational Medicine*, **2022**, 14, eabm1375	17.5	2
140	Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow. *Haematologica*, **2018**, 103, e270-e273	6.6	1

139	Quality of Life: A Tiebreaker in CEBPA Double-Mutated Acute Myeloid Leukemia. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1535-1536	4.7	1
138	Tissue polymerase chain reaction for the diagnosis of cytomegalovirus disease after allogeneic hematopoietic cell transplantation. *American Journal of Hematology*, **2017**, 92, E19-E20	7.1	1
137	Reply to Jaber et al.. *Infection Control and Hospital Epidemiology*, **2008**, 29, 189-190	2	1
136	Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123□CD3 Bispecific Dart□ Molecule, in Acute Myeloid Leukemia. *Blood*, **2020**, 136, 26-28	2.2	1
135	Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma. *Blood*, **2020**, 136, 3-4	2.2	1
134	Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib. *Blood*, **2019**, 134, 2325-2325	2.2	1
133	Identification of Small Molecule Kinase Inhibitors That Potently and Reversibly Block Chimeric Antigen Receptor T Cell Proliferation and Cytotoxicity. *Blood*, **2019**, 134, 2068-2068	2.2	1
132	Single-Cell Transcriptomic and Proteomic Diversity in Multiple Myeloma. *Blood*, **2019**, 134, 5531-5531	2.2	1
131	Phenotypic and Functional Analysis of T-Cells Mobilized in HLA-Matched Sibling Donors Following Treatment with the Chemokine Antagonist AMD3100.. *Blood*, **2006**, 108, 3001-3001	2.2	1
130	Kinetics of Autologous Stem Cell Mobilization Failure: Comparison of AMD3100/G-CSF, G-CSF, GM-/G-CSF, and Chemotherapy/G-CSF on Remobilization Success.. *Blood*, **2006**, 108, 3380-3380	2.2	1
129	Salvage Therapy with Flag/Idarubicin/Mylotarg (Flag-IM) Results in a Superior CR/CRp Rate and Low Toxicity When Compared to Mitoxantrone/Etoposide/Cytarabine (MEC) in Patients with Relapsed and Refractory AML.. *Blood*, **2006**, 108, 4576-4576	2.2	1
128	CXCR4/SDF-1 Is a Key Regulator for Leukemia Migration and Homing to the BM: Impact of AMD3100 on In Vivo Response to Chemotherapy.. *Blood*, **2006**, 108, 569-569	2.2	1
127	FLAG-IM (Fludarabine, Ara-C, G-CSF, Idarubicin, Mylotarg) Is an Effective Salvage Regimen Producing High Rates of Remission (CR+CRi) in Relapsed/Refractory AML.. *Blood*, **2007**, 110, 1855-1855	2.2	1
126	Mobilization of Normal Mouse Progenitors and Acute Promyelocytic Leukemia (APL) Cells with Inhibitors of CXCR4 and VLA-4 in Splenectomized and Unsplenectomized Mice.. *Blood*, **2007**, 110, 2219-2219	2.2	1
125	Transplanted CD34+ Cell Dose Is Associated with Long-Term Platelet Count Following Autologous Hematopoietic Stem Cell Transplant in Patients with Non-Hodgkin□ Lymphoma and Multiple Myeloma.. *Blood*, **2008**, 112, 2175-2175	2.2	1
124	Similar 1 Year Survival of Patients Receiving Plerixafor (Mozobil*□) Plus G-CSF Versus Placebo Plus G-CSF Mobilized Autologous Grafts: Results From Two Phase 3 Randomized Trials in Patients with NHL or MM Undergoing Autologous Transplantation After Front-Line or Rescue Mobilization.. *Blood*, **2009**, 114, 2319-2319	2.2	1
123	Phase-2 Study of Pomalidomide in Advanced Corticosteroid-Resistant Chronic Graft-Versus-Host Disease (cGVHD).. *Blood*, **2009**, 114, 3326-3326	2.2	1
122	Prognostic Significance of PET Imaging in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation.. *Blood*, **2009**, 114, 3417-3417	2.2	1

121	Allogeneic Hematopoietic Cell Transplantation Can Cure Some Patients with Acute Leukemia in Relapse or Primary Induction Failure: A CIBMTR Study.. *Blood*, **2009**, 114, 528-528	2.2	1
120	Phase I Study of Intravenous Plerixafor Added to a Mobilization Regimen of G-CSF In Lymphoma Patients Undergoing Autologous Stem Cell Collection. *Blood*, **2010**, 116, 823-823	2.2	1
119	Complete Sequencing and Comparison of 12 Normal Karyotype M1 AML Genomes with 12 t(15;17) Positive M3-APL Genomes. *Blood*, **2011**, 118, 404-404	2.2	1
118	Clinical Burden and Progression of Myelofibrosis in a Controlled Study Population of Placebo-Treated Patients (COMFORT-I). *Blood*, **2011**, 118, 5146-5146	2.2	1
117	Defining The Mechanism Involved In The Inhibition Of GvHD By Azacytidine In Vivo Through The Use Of FoxP3 Diphtheria Toxin Receptor (Foxp3DTR) Donor T Cells. *Blood*, **2013**, 122, 134-134	2.2	1
116	Acute Myeloid Leukemia Patients with Pre-Transplant Ablated Marrows Have Similar Rates of Survival and Relapse Compared to Patients in Complete Remission after Allogeneic Hematopoietic Cell Transplantation. *Blood*, **2014**, 124, 2557-2557	2.2	1
115	A Phase I Study of Vosaroxin Plus Azacitidine for Patients with Myelodysplastic Syndrome. *Blood*, **2015**, 126, 1686-1686	2.2	1
114	CD34+-Selected Infusions of Fresh or Cryopreserved Peripheral Blood Stem Cells for the Treatment of Poor Graft Function Following Allogeneic Hematopoietic Stem Cell Transplant. *Blood*, **2015**, 126, 3098-3098	2.2	1
113	Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy. *Blood*, **2015**, 126, 610-610	2.2	1
112	Expansion and Maintenance of Hematopoietic Stem and Progenitor Cells in Course of Long-Term Inhibition of CXCR4/CXCL12 Signaling. *Blood*, **2016**, 128, 2648-2648	2.2	1
111	Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.. *Journal of Clinical Oncology*, **2016**, 34, 7012-7012	2.2	1
110	Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials. *Blood*, **2021**, 138, 2550-2550	2.2	1
109	Cedar Trial in Progress: A First in Human, Phase 1/2 Study of the Correction of a Single Nucleotide Mutation in Autologous HSCs (GPH101) to Convert HbS to HbA for Treating Severe SCD. *Blood*, **2021**, 138, 1864-1864	2.2	1
108	Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial. *Blood*, **2021**, 138, 475-475	2.2	1
107	A Long-Acting Pharmacological Grade Interleukin-7 Molecule Logarithmically Accelerates Ucart Proliferation, Differentiation, and Tumor Killing. *Blood*, **2018**, 132, 2199-2199	2.2	1
106	Modeling Sézary Syndrome for Immunophenotyping and Anti-Tumor Effect of Ucart and Long-Acting Interleukin-7 Combination Therapy. *Blood*, **2018**, 132, 340-340	2.2	1
105	Donor-to-Recipient Weight Ratio Is Independently Associated with CD34+ Yield in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. *Blood*, **2014**, 124, 2456-2456	2.2	1
104	Targeting VLA-4 to Reduce GvHD. *Blood*, **2014**, 124, 3829-3829	2.2	1

103	DNMT3A-Dependent DNA Methylation May Act As a Tumor Suppressor-Not a Tumor Promoter-during AML Progression. *Blood*, **2016**, 128, 1050-1050	2.2	1
102	A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 2223-2228	4.7	1
101	Immunotherapy for T-Cell ALL and T-Cell NHL. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20 Suppl 1, S56-S58	2	1
100	Mobilization of Peripheral Blood Hematopoietic Cells for Autologous HCT **2016**, 452-462		1
99	Can planned CD34+ stem cell boost prevent poor graft function after peripheral blood haploidentical hematopoietic transplantation?. *Leukemia and Lymphoma*, **2021**, 62, 749-751	1.9	1
98	Selective targeting of histone modification fails to prevent graft versus host disease after hematopoietic cell transplantation. *PLoS ONE*, **2018**, 13, e0207609	3.7	1
97	Nanoparticle T cell engagers for the treatment of acute myeloid leukemia. *Oncotarget*, **2021**, 12, 1878-1885	3.5	1
96	PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery.. *NAR Cancer*, **2022**, 4, zcac014	5.2	1
95	Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival.. *Scientific Reports*, **2022**, 12, 30	4.9	0
94	Generation of Treg-Like Cells from CD4+CD25- T Cells Via Epigenetic Modification Using a Demethylating Agent Decitabine.. *Blood*, **2007**, 110, 62-62	2.2	0
93	Decitabine for Older AML Patients: An Effective Therapy Associated with Short Hospitalization and No Invasive Fungal Infection.. *Blood*, **2010**, 116, 1063-1063	2.2	0
92	A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/ Lymphoblastic Lymphoma (LBL). *Blood*, **2021**, 138, 4829-4829	2.2	0
91	Pre-Infusion Neurofilament Light Chain (NfL) Levels Predict the Development of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) - a Multicenter Retrospective Study. *Blood*, **2021**, 138, 2841-2841	2.2	0
90	A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes. *Leukemia and Lymphoma*, **2021**, 62, 1441-1449	1.9	0
89	Genetic and Transcriptional Contributions to Relapse in Normal Karyotype Acute Myeloid Leukemia.. *Blood Cancer Discovery*, **2022**, 3, 32-49	7	0
88	A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma. *Scientific Reports*, **2021**, 11, 19343	4.9	0
87	In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [F]FDG and [Cu]Cu-LLP2A PET. *EJNMMI Research*, **2021**, 11, 97	3.6	0
86	The impact of diabetes mellitus and other comorbidities on hematopoietic stem cell collection and hematologic recovery post-transplantation. *Leukemia and Lymphoma*, **2017**, 58, 241-243	1.9	

85	Allogeneic hematopoietic cell transplantation in morphologic leukemia-free aplastic state. *American Journal of Hematology*, **2017**, 92, E549-E552	7.1
84	The effect of donor type on outcomes in adults with acute myeloid leukemia after reduced-intensity hematopoietic peripheral blood cell transplant - a retrospective study. *Transplant International*, **2020**, 33, 1089-1098	3
83	A phase I study of thymoglobulin for relapsed or refractory multiple myeloma. *Leukemia and Lymphoma*, **2016**, 57, 453-455	1.9
82	Extending the duration of response in chronic myelogenous leukemia: targeted therapy with sequential tyrosine kinase inhibitors. *Oncology Reviews*, **2009**, 3, 59-70	4.3
81	Stem cells stat, please!. *Blood*, **2003**, 102, 2711-2711	2.2
80	Myeloma Cell Associated Therapeutic Protein Discovery Using Single Cell RNA-Seq Data. *Blood*, **2020**, 136, 4-5	2.2
79	Signaling Gene Mutations Are Characterized By Diverse Patterns of Expansion and Contraction during Progression from MDS to Secondary AML. *Blood*, **2020**, 136, 2-3	2.2
78	TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia. *Blood*, **2020**, 136, 3-4	2.2
77	Upfront Alternative Donor Transplant Versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack Fully HLA Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies. on Behalf of the Severe Aplastic Anemia Working Party of European Group for Blood and Marrow Transplantation (SAAWP of EBMT). *Blood*, **2020**, 136, 6-7	2.2
76	Addressing Relapsed Disease Following Hematopoietic Stem Cell Transplantation. *Blood*, **2020**, 136, SCI1-SCI1	2.2
75	Flotetuzumab and Other Cellular Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells in Vitro and In Vivo. *Blood*, **2020**, 136, 22-23	2.2
74	Increased early mortality after fludarabine and melphalan conditioning with peripheral blood grafts in haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. *Leukemia and Lymphoma*, **2021**, 1-5	1.9
73	Adverse Outcomes in Acute Myeloid Leukemia Are Associated with Tumor Cell-Mediated Immunosuppression. *Blood*, **2021**, 138, 800-800	2.2
72	3D Tissue-Engineered Bone Marrow Culture Predicts Patient Response to Drugs in Multiple Myeloma. *Blood*, **2021**, 138, 2690-2690	2.2
71	Immunophenotypic and Single-Cell Transcriptional Profiling of CD34+ Hematopoietic Stem and Progenitor Cells Mobilized with Motixafortide (BL-8040) and G-CSF Versus Plerixafor and G-CSF Versus Placebo and G-CSF: A Correlative Study of the Genesis Trial. *Blood*, **2021**, 138, 3816-3816	2.2
70	Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial. *Blood*, **2021**, 138, 2849-2849	2.2
69	Single-Cell RNA-Seq Analysis of CD138-Depleted Bone Marrow Samples Reveals Genetic Alterations and Disease Progression Correlate with Tumor and Bone Marrow Immune Microenvironment in the Mmrf Commpass Study. *Blood*, **2021**, 138, 2691-2691	2.2
68	Use of Belimumab for Prophylaxis of Chronic Graft-Versus-Host Disease. *Blood*, **2021**, 138, 3904-3904	2.2

67	A Murine Xenograft Model for Human T Cell Mediated Graft Versus Host Disease.. *Blood*, **2004**, 104, 4977-4977	2.2
66	GMP Scale up for a Clinical Gene Therapy Trial - High Efficiency Human T Cell Expansion and Transduction in a Closed Culture System Utilizing Serumfree Medium and Low IL-2 Concentrations.. *Blood*, **2004**, 104, 5250-5250	2.2
65	Reduced Intensity Allografts for Acute Myeloid Leukemia: Defining the Role of Conditioning and Donor Alloreactivity.. *Blood*, **2004**, 104, 5191-5191	2.2
64	In Vivo Suicide Gene Therapy of Human T Lymphocytes To Prevent Graft Versus Host Disease in a Murine Xenograft Model.. *Blood*, **2004**, 104, 4979-4979	2.2
63	Once Daily Ganciclovir (ODG) as Initial Pre-Emptive Therapy (PT) Delayed until Threshold Viral Load ≥10,000 Copies/ml: A Safe and Effective Strategy for Post-Allogeneic Stem Cell Transplant (ASCT) Patients.. *Blood*, **2004**, 104, 3158-3158	2.2
62	Once Weekly Bortezomib (Velcade) Preserves Bone Health by a Direct Effect on Osteoclast Function Independent of Its Effect on the Malignant Plasma Cells.. *Blood*, **2005**, 106, 3458-3458	2.2
61	Inosine Monophosphate Dehydrogenase II Mutant (Thr-333-Ile + Ser-351-Tyr) Does Not Confer Resistance to Mycophenolic Acid In Vivo.. *Blood*, **2005**, 106, 5226-5226	2.2
60	Naive and Ex Vivo Activated Human T Cells Generate Consistent Engraftment and Lethal Graft-Versus-Host Disease (GvHD) in NOD SCID β2M Null Mice: A New Xenogeneic Model for GvHD.. *Blood*, **2005**, 106, 3106-3106	2.2
59	Comparison of the Proliferative Kinetics, GVHD Potential and GCV Sensitivity of Naive and Transduced and Selected Murine T Cells after Allogeneic BMT.. *Blood*, **2005**, 106, 5257-5257	2.2
58	Kinetics of Hematopoietic Progenitor Cell Mobilization with Cyclophosphamide or Cyclophosphamide Plus AMD3100 Using a Mouse Model.. *Blood*, **2005**, 106, 5217-5217	2.2
57	Large Scale Ex Vivo GMP Expanded, Activated Human T Cells Consistently Induce Lethal GvHD in a Mouse Xenotransplant Model - A New Way To Study Treatments for Acute GvHD.. *Blood*, **2005**, 106, 5242-5242	2.2
56	Evaluation of the Phenotype and GVHD-Inducing Potential of Splenic T Cells Isolated from G-CSF, AMD3100, or G-CSF and AMD3100 Pretreated Allogeneic Donors.. *Blood*, **2005**, 106, 5224-5224	2.2
55	A Randomized, Double Blind Trial, of Hydroxychloroquine for the Prevention of Graft-Versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation.. *Blood*, **2005**, 106, 1800-1800	2.2
54	Impact of Disease and Mobilizing Agents on Initial and Remobilization Failure.. *Blood*, **2006**, 108, 5222-5222	2.2
53	Forced Expression of the [illegible]Mutant Inosine Monophosphate Dehydrogenase II Results in Physiologically Significant Resistance to Mycophenolic Acid In Vitro.. *Blood*, **2006**, 108, 5480-5480	2.2
52	Prolonged Engraftment and/or Primary Graft Failure Following Allogenic Stem Cell Transplant in Patients Treated with Dasatinib.. *Blood*, **2006**, 108, 5259-5259	2.2
51	In Vivo Bioluminescence Imaging (BLI) and Sequential 18F]FHBG microPET Imaging Studies of Human T Cell (huT) Trafficking, Expansion and Xenogeneic Graft-Versus-Host-Disease (XGVHD) Following Different Routes of T Cell Administration.. *Blood*, **2006**, 108, 5178-5178	2.2
50	Allogeneic Recipients of Ex-Vivo Manipulated Donor T Cells Have Altered Plasma Analyte Profiles Compared to Recipients of Unmanipulated T Cells.. *Blood*, **2006**, 108, 3227-3227	2.2

49	A Phase II Study of Intravenous Azacitidine Alone in Patients with Myelodysplastic Syndromes NCT00384956.. *Blood*, **2007**, 110, 1451-1451	2.2
48	M2-10B4 Mesenchymal Stromal Cells Confer an In Vitro Protective Effect of Murine mCGPR/+ Acute Promyelocytic Leukemic Cells Against Chemotherapy.. *Blood*, **2007**, 110, 2844-2844	2.2
47	Kinetics of Stem Cell and Lymphoid Subset Mobilization in Response to Intravenous (IV) AMD3100 in Mouse and Man.. *Blood*, **2007**, 110, 1203-1203	2.2
46	Conditioning for Hematopoietic Stem Cell Transplantation Using Antibody-Drug Conjugate Targeting CD45 Permits Engraftment across Immunologic Barriers. *Blood*, **2018**, 132, 2035-2035	2.2
45	Characterization of Germline Variants in Multiple Myeloma. *Blood*, **2018**, 132, 4499-4499	2.2
44	Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Transplantation and Phenotypic Characterization of the Leukapheresis Product. *Blood*, **2018**, 132, 118-118	2.2
43	Comprehensive Multi-Omics Analysis of Gene Fusions in a Large Multiple Myeloma Cohort. *Blood*, **2018**, 132, 1898-1898	2.2
42	Single-Cell Pathway Enrichment and Regulatory Profiling of Multiple Myeloma across Disease Stages. *Blood*, **2019**, 134, 364-364	2.2
41	CD45-ADC Plus Janus Kinase (JAK) Inhibitors As Conditioning for MHC-Mismatched Murine Hematopoietic Stem Cell Transplantation Is Associated with Minimal Toxicity and Graft Versus Host Disease. *Blood*, **2019**, 134, 3200-3200	2.2
40	Blocking JAK1/JAK2 While Sparing JAK3 Not Only Prevents GvHD but Also Promotes Damaged Tissue Repair. *Blood*, **2019**, 134, 4420-4420	2.2
39	A Study of High Dose Lenalidomide Induction and Low Dose Lenalidomide Maintenance for Patients with Hypomethylating Agent Refractory MDS. *Blood*, **2014**, 124, 1931-1931	2.2
38	Dual-Function Anti-CD47mAbs Induce Tumor Cell Death and Promote Phagocytosis Resulting in Enhanced in Vivo Efficacy. *Blood*, **2014**, 124, 991-991	2.2
37	Dysregulated Overexpression of S100A8 and S100A9 Calgranulin Family Proteins in IFNR-/- Allogeneic T Cells Is Associated with Reduced Graft Versus Host Disease in Vivo. *Blood*, **2014**, 124, 3828-3828	2.2
36	Impact of Remission Status on Outcomes in AML Patients ≥60 Years of Age after Allogeneic Stem Cell Transplantation. *Blood*, **2014**, 124, 1263-1263	2.2
35	Chemotherapy Versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplant: A Retrospective Review. *Blood*, **2014**, 124, 3944-3944	2.2
34	A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia. *Blood*, **2014**, 124, 5292-5292	2.2
33	Preclinical Studies of the IAP Antagonist Debio 1143 in Combination with Cytarabine or Doxorubicin in a Mouse Model of AML. *Blood*, **2014**, 124, 5296-5296	2.2
32	Remobilization with G-CSF Is Less Effective Than the Initial Mobilization in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. *Blood*, **2014**, 124, 850-850	2.2

31	A Second Generation, Multiple Myeloma-Specific, Targeted Sequencing Platform for Detecting Translocations, Copy Number Alterations, and Single Nucleotide Variants. *Blood*, **2015**, 126, 4207-4207	2.2
30	Addition of Mycophenolate Mofetil to Methotrexate and Tacrolimus Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation. *Blood*, **2015**, 126, 3144-3144	2.2
29	Phase II Study of Propylene Glycol-Free Melphalan (Evomela) Combined with Carmustine, Etoposide, and Cytarabine (BEAM) for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. *Blood*, **2015**, 126, 3196-3196	2.2
28	Reduced Intensity Hematopoietic Cell Transplantation in Active Disease AML Is Associated with Leukemia Free Survival and Relapse Comparable to Myeloablative Conditioning. *Blood*, **2016**, 128, 3477-3477	2.2
27	Haploidentical Transplant with Peripheral Blood Hematopoietic Cell Grafts in Older Adults with AML or MDS. *Blood*, **2016**, 128, 4658-4658	2.2
26	Absolute Lymphocyte Count Recovery Predicts Post Transplant Outcomes in Peripheral Blood Haploidentical Transplantation. *Blood*, **2016**, 128, 4698-4698	2.2
25	Clonal Evolution of Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation. *Blood*, **2016**, 128, 1528-1528	2.2
24	A Single-Institution Randomized Prospective Trial of Pre-Emptive Therapy with Oral Valganciclovir Compared with IV Ganciclovir for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplant (aHSCT), Delayed until Viral Load (VL) >10,000 Copies/Ml or >5,000 Copies/Ml X 2. *Blood*, **2008**, 112, 4340-4340	2.2
23	Generation of Treg-Like Cells from CD4+CD25- T Cells Occurs Via Both Foxp3 Dependent and Independent Pathways. *Blood*, **2008**, 112, 813-813	2.2
22	Azacitidine-Induced Changes in the MDS Methylome Are Associated with Clinical Responses. *Blood*, **2008**, 112, 2691-2691	2.2
21	Allogeneic Stem Cell Transplantation Conditioning for MDS and AML with Clofarabine, Cytarabine and ATG. *Blood*, **2008**, 112, 4427-4427	2.2
20	MCL1 Haploinsufficiency Protects Mice From MYC-Induced Acute Myeloid Leukemia.. *Blood*, **2009**, 114, 764-764	2.2
19	Epigenetic Control of GvHD and Gvl Using the Hypomethylating Agent Azacitidine.. *Blood*, **2009**, 114, 2447-2447	2.2
18	Comparable Disease-Free and Overall Survival After Well-Matched Unrelated Donor and Matched Sibling Donor Transplantation in Acute Myeloid Leukemia with Adverse Risk Karyotype in First Complete Remission: A Report From the Acute Leukemia Working Committee of the Centre for International Blood and Marrow Transplant Research.. *Blood*, **2009**, 114, 526-526	2.2
17	Recurrent DNMT3A Mutations In Patients with Myelodysplastic Syndrome. *Blood*, **2010**, 116, 608-608	2.2
16	Detection of Novel Mutations In MDS/AML by Whole Genome Sequencing. *Blood*, **2010**, 116, 299-299	2.2
15	A Retrospective Review of Response to Donor Leukocyte Infusions In Adults with Acute Myeloid Leukemia After Reduced Intensity Conditioned Allogeneic Hematopoietic Cell Transplantation.. *Blood*, **2010**, 116, 4512-4512	2.2
14	Donor Dual TCR T Cells Preferentially Expand and Mediate Pathologic Alloreactivity in Acute Graft Versus Host Disease. *Blood*, **2011**, 118, 1972-1972	2.2

13	Older Adults with Chronic Myelogenous Leukemia (CML), During the Tyrosine Kinase Inhibitor (TKI) Era, Can Be Successfully Treated with Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplant (HCT) Using Sibling or Unrelated Donors: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. *Blood*, **2011**, 118, 494-494	2.2
12	A Phase 1 Study of Concomitant High Dose Lenalidomide and 5-Azacytidine Induction in the Treatment of Acute Myeloid Leukemia,. *Blood*, **2011**, 118, 3616-3616	2.2
11	Genomic Landscape of Immunoglobulin Light Chain (AL) Amyloidosis and Comparative Analyses with Related Malignant Plasma Cell Disorder- Multiple Myeloma. *Blood*, **2011**, 118, 809-809	2.2
10	Effect of a Novel Nucleoside Analogue, Triciribine Phosphate (TCN-P) on Murine Acute Graft-Vrs-Host Disease (aGvHD). *Blood*, **2011**, 118, 2977-2977	2.2
9	Phase I Study of Cladribine (2-chlorodeoxyadenosie), Cytarabine and G-CSF Based Induction Therapy (CLAG) with ATRA (All-trans retinoic acid) and Midostaurin for Relapsed/Refractory AML,. *Blood*, **2011**, 118, 3609-3609	2.2
8	High Throughput Digital Quantification of Genomic Copy Number Alterations in Multiple Myeloma. *Blood*, **2011**, 118, 1830-1830	2.2
7	Genome-Wide Copy Number Analyses Correlated with Outcomes in Untreated Multiple Myeloma Patients. *Blood*, **2012**, 120, 3991-3991	2.2
6	Use of FoxP3 Diptheria Toxin Receptor (Foxp3DTR) Donor T Cells to Define the Mechanism Involved in the Inhibition of GvHD by Azacytidine in Vivo. *Blood*, **2012**, 120, 4113-4113	2.2
5	A Phase I Dose Escalation Study Of Oral Bexarotene In Combination With Intravenous Decitabine In Patients With AML. *Blood*, **2013**, 122, 3931-3931	2.2
4	Plerixafor, G-CSF and Azacitidine For The Treatment Of MDS: Results Of a Phase I Trial. *Blood*, **2013**, 122, 2816-2816	2.2
3	Targeting Bone Marrow Lymphoid Niches In Acute Lymphoblastic Leukemia. *Blood*, **2013**, 122, 1398-1398	2.2
2	Marrow Microenvironment and Biology of Mobilization of Stem Cells **2016**, 50-67	
1	Highlights in chronic graft-vs-host disease from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary. *Clinical Advances in Hematology and Oncology*, **2021**, 19 Suppl 8, 20-23	0.6